Antiviral hyperactivation-limiting therapeutics as a novel class for the treatment of HIV/AIDS: focus on VS411. (Q37851515)

24 August 2017

1 reference

title

Antiviral hyperactivation-limiting therapeutics as a novel class for the treatment of HIV/AIDS: focus on VS411. (English)

1 reference

24 August 2017

0 references

Alessia Uglietti

1

1 reference

24 August 2017

Renato Maserati

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

11 March 2011

1 reference

Expert Opinion on Investigational Drugs

24 August 2017

published in

1 reference

24 August 2017

volume

20

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

559-565

1 reference

Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

HIV policy: the path forward--a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virus–Infected Patients with Sustained Viral Suppression during Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Microbial translocation is a cause of systemic immune activation in chronic HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

A checkpoint in the cell cycle progression as a therapeutic target to inhibit HIV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Cell dysfunction and depletion in AIDS: the programmed cell death hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

The impact of HIV on naïve T-cell homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

The dynamics of CD4+ T-cell depletion in HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in [corrected] HIV/AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Reduction of immune activation with chloroquine therapy during chronic HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Antiretroviral effect of lovastatin on HIV-1-infected individuals without highly active antiretroviral therapy (The LIVE study): a phase-II randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Hydroxyurea: new insights on an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Dermatological adverse effects with the antimalarial drug mefloquine: a review of 74 published case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

The role of hydroxyurea in the management of sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

"Virostatics" as a potential new class of HIV drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of beta-chemokines: a strategy to inhibit R5 HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Direct analysis of mitochondrial toxicity of antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

HIV-1 infection initiates an inflammatory cascade in human renal tubular epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.565047

10.1517/13543784.2011.565047

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference